1. Au@Pt@Pd nanozymes based lateral flow immunoassay for quantitative detection of SARS-CoV-2 nucleocapsid protein in nasal swab samples.
- Author
-
Li C, Lu J, Xiang C, Zhang E, Tian X, Zhang L, Li T, and Li C
- Subjects
- Humans, Immunoassay methods, Phosphoproteins analysis, Phosphoproteins immunology, Gold chemistry, SARS-CoV-2 immunology, Palladium chemistry, Metal Nanoparticles chemistry, Coronavirus Nucleocapsid Proteins immunology, Coronavirus Nucleocapsid Proteins analysis, Limit of Detection, Platinum chemistry, COVID-19 diagnosis, COVID-19 virology
- Abstract
Three-metal-core-shell nanoparticles (Au@Pt@PdNPs) providing excellent peroxidase-like activity were applied in lateral flow immunoassay (LFIA), designated as Au@Pt@Pd-LFIA, for detecting the nucleocapsid protein (NP) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An Au@Pt@Pd-LFIA was developed for quantitatively testing of SARS-CoV-2 NP with a range 0.12-31.25 ng/mL. The limit of detection (LOD) of Au@Pt@Pd-LFIA strip was 0.06 ng/mL, which was 16-fold or eightfold more sensitive than that of the gold lateral flow immunoassay (Au-LFIA) and the gold flower flow immunoassay (AF-LFIA) strips, respectively. For detection of clinical samples from nasal swabs using test strips, Au@Pt@Pd-LFIA had 84.09% sensitivity, 100% specificity, and 92.55% accuracy. In terms of detection time, the testing of Au@Pt@Pd-LFIA strip was 16 min similar to Au-LFIA (15 min) and AF-LFIA (10 min), but much shorter than ELISA (2 h). In conclusion, Au@Pt@Pd-LFIA is a sensitive, rapid, and simple test for quantitative detection of SARS-CoV-2 NP in nasal swab samples., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF